Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company's products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate,… Read more
Egetis Therapeutics AB (publ) (EGTX) - Net Assets
Latest net assets as of June 2025: Skr355.10 Million SEK
Based on the latest financial reports, Egetis Therapeutics AB (publ) (EGTX) has net assets worth Skr355.10 Million SEK as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr654.40 Million) and total liabilities (Skr299.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr355.10 Million |
| % of Total Assets | 54.26% |
| Annual Growth Rate | 33.15% |
| 5-Year Change | -21.72% |
| 10-Year Change | 926.19% |
| Growth Volatility | 318.73 |
Egetis Therapeutics AB (publ) - Net Assets Trend (2008–2024)
This chart illustrates how Egetis Therapeutics AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Egetis Therapeutics AB (publ) (2008–2024)
The table below shows the annual net assets of Egetis Therapeutics AB (publ) from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr492.90 Million | -9.66% |
| 2023-12-31 | Skr545.60 Million | +7.78% |
| 2022-12-31 | Skr506.20 Million | -3.95% |
| 2021-12-31 | Skr527.04 Million | -16.29% |
| 2020-12-31 | Skr629.63 Million | +157.12% |
| 2019-12-31 | Skr244.88 Million | +11.63% |
| 2018-12-31 | Skr219.36 Million | -27.77% |
| 2017-12-31 | Skr303.71 Million | -22.04% |
| 2016-12-31 | Skr389.56 Million | +711.05% |
| 2015-12-31 | Skr48.03 Million | -47.02% |
| 2014-12-31 | Skr90.66 Million | +93.08% |
| 2013-12-31 | Skr46.95 Million | -12.95% |
| 2012-12-31 | Skr53.94 Million | -38.38% |
| 2011-12-31 | Skr87.53 Million | +1152.27% |
| 2010-12-31 | Skr6.99 Million | +23.92% |
| 2009-12-31 | Skr5.64 Million | +11.75% |
| 2008-12-31 | Skr5.05 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Egetis Therapeutics AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 160925061600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr20.40 Million | 4.14% |
| Other Comprehensive Income | Skr24.90 Million | 5.05% |
| Other Components | Skr2.06 Billion | 417.53% |
| Total Equity | Skr492.80 Million | 100.00% |
Egetis Therapeutics AB (publ) Competitors by Market Cap
The table below lists competitors of Egetis Therapeutics AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mayur Uniquoters Ltd
NSE:MAYURUNIQ
|
$101.68 Million |
|
LCY Technology Corp
TW:4989
|
$101.69 Million |
|
Sport Lisboa e Benfica - Futebol, SAD
LSE:0M7V
|
$101.70 Million |
|
Jean Co Ltd
TW:2442
|
$101.72 Million |
|
Bank Jabar
JK:BJBR
|
$101.58 Million |
|
Rexon Industrial Corp Ltd
TW:1515
|
$101.55 Million |
|
Vieworks Co. Ltd
KQ:100120
|
$101.54 Million |
|
Shanghai Taihe Water Environmental Technology Development Co Ltd
SHG:605081
|
$101.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Egetis Therapeutics AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 545,600,000 to 492,800,000, a change of -52,800,000 (-9.7%).
- Net loss of 343,600,000 reduced equity.
- Share repurchases of 1,500,000 reduced equity.
- New share issuances of 301,500,000 increased equity.
- Other comprehensive income increased equity by 8,200,000.
- Other factors decreased equity by 17,400,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-343.60 Million | -69.72% |
| Share Repurchases | Skr1.50 Million | -0.3% |
| Share Issuances | Skr301.50 Million | +61.18% |
| Other Comprehensive Income | Skr8.20 Million | +1.66% |
| Other Changes | Skr-17.40 Million | -3.53% |
| Total Change | Skr- | -9.68% |
Book Value vs Market Value Analysis
This analysis compares Egetis Therapeutics AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.37x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.34x to 3.37x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | Skr15.71 | Skr5.42 | x |
| 2009-12-31 | Skr17.56 | Skr5.42 | x |
| 2010-12-31 | Skr18.99 | Skr5.42 | x |
| 2011-12-31 | Skr3.95 | Skr5.42 | x |
| 2012-12-31 | Skr1.97 | Skr5.42 | x |
| 2013-12-31 | Skr1.69 | Skr5.42 | x |
| 2014-12-31 | Skr3.01 | Skr5.42 | x |
| 2015-12-31 | Skr1.53 | Skr5.42 | x |
| 2016-12-31 | Skr11.85 | Skr5.42 | x |
| 2017-12-31 | Skr5.64 | Skr5.42 | x |
| 2018-12-31 | Skr4.08 | Skr5.42 | x |
| 2019-12-31 | Skr4.29 | Skr5.42 | x |
| 2020-12-31 | Skr8.57 | Skr5.42 | x |
| 2021-12-31 | Skr2.93 | Skr5.42 | x |
| 2022-12-31 | Skr2.61 | Skr5.42 | x |
| 2023-12-31 | Skr2.10 | Skr5.42 | x |
| 2024-12-31 | Skr1.61 | Skr5.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Egetis Therapeutics AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -69.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -745.34%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.61x
- Recent ROE (-69.72%) is below the historical average (-41.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -11.08% | 0.00% | 0.00x | 1.06x | Skr-1.06 Million |
| 2009 | -23.86% | 0.00% | 0.00x | 1.05x | Skr-1.91 Million |
| 2010 | -54.37% | -142559.04% | 0.00x | 1.21x | Skr-4.50 Million |
| 2011 | -37.98% | 0.00% | 0.00x | 1.04x | Skr-42.00 Million |
| 2012 | -62.77% | 0.00% | 0.00x | 1.12x | Skr-39.25 Million |
| 2013 | -54.41% | 0.00% | 0.00x | 1.09x | Skr-30.24 Million |
| 2014 | -53.41% | 0.00% | 0.00x | 1.14x | Skr-57.49 Million |
| 2015 | -91.26% | 0.00% | 0.00x | 1.09x | Skr-48.64 Million |
| 2016 | -9.81% | 0.00% | 0.00x | 1.02x | Skr-77.18 Million |
| 2017 | -28.95% | -647.29% | 0.04x | 1.04x | Skr-118.31 Million |
| 2018 | -38.75% | -301.31% | 0.12x | 1.10x | Skr-106.94 Million |
| 2019 | -25.09% | -74.40% | 0.31x | 1.10x | Skr-85.92 Million |
| 2020 | -28.45% | -440.51% | 0.05x | 1.42x | Skr-242.08 Million |
| 2021 | -19.87% | -273.85% | 0.07x | 1.08x | Skr-157.43 Million |
| 2022 | -37.44% | -842.22% | 0.04x | 1.11x | Skr-240.12 Million |
| 2023 | -59.92% | -567.53% | 0.08x | 1.39x | Skr-381.46 Million |
| 2024 | -69.72% | -745.34% | 0.06x | 1.61x | Skr-392.88 Million |
Industry Comparison
This section compares Egetis Therapeutics AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Egetis Therapeutics AB (publ) (EGTX) | Skr355.10 Million | -11.08% | 0.84x | $101.65 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |